# Intra-IMMUSG

Source: https://onco.cc/companies/intra-immusg/  
OnCo record `intra-immusg` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Intra-IMMUSG is a Singapore-based biotechnology company running 3 late-stage cancer trials.

## Summary

Intra-IMMUSG, based in Singapore, Singapore, is a biotechnology company. Intra-ImmuSG is a Phase 2 clinical-stage biotechnology company developing antibody-based cancer immunotherapies that target intracellular tumour antigens exposed on the cancer cell surface. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3). The largest, NCT07541001 (PRL3-Zumab in Patients With Advanced Solid Tumours), plans to enrol 60 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Intra-IMMUSG Pte Ltd
- Tags: ctgov-sponsor
- HQ: Singapore
- Type: biotech
- Website: https://www.intra-immusg.com

## Sources

- Official website: https://www.intra-immusg.com
- ClinicalTrials.gov: trials led by Intra-IMMUSG: https://clinicaltrials.gov/search?lead=Intra-IMMUSG%20Pte%20Ltd

## Connected records

- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors](https://onco.cc/trials/nct04452955/), [Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients](https://onco.cc/trials/nct07290088/), [PRL3-Zumab in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07541001/)

---
JSON: https://onco.cc/api/v1/entities/intra-immusg.json